Andrew Benjamin Nixon, PhD

Professor in Medicine
Member of the Duke Cancer Institute
Campus mail 133 Jones, Research Drive, Durham, NC 27710
Phone (919) 613-7883
Email address anixon@duke.edu

Andrew Nixon, PhD, MBA (Professor of Medicine) is Director of the Phase I Biomarker Laboratory, which brings together clinical, translational and basic research to pursue the development of novel biomarkers defining mechanisms of sensitivity, resistance, and toxicity to given therapeutic drug classes, particularly anti-angiogenic agents. Additionally, the laboratory has been appointed as a Molecular Reference Laboratory for the Alliance oncology cooperative group, a national clinical trial research group sponsored by the National Cancer Institute. The laboratory has quality control procedures in place to address many of the issues involved in clinical trial research including determination of sample quantity, sample integrity, and sample heterogeneity. We have spent considerable time developing robust assays that utilize limited amounts of specimen while providing high quality data. Multiplex ELISA and gene expression arrays are used to analyze serially collected blood and paraffin samples archived from cancer patient clinical trials. This work has the potential to improve the efficacy and toxicity of current therapies and to guide the development of the next generation of anti-angiogenesis therapies for cancer and other diseases.

Education and Training

  • M.B.A., Duke University, 2007
  • Ph.D., Wake Forest University, 1997

Grants

Publications

Nixon, Andrew B., Susan Halabi, Yingmiao Liu, Mark D. Starr, John C. Brady, Ivo Shterev, Bin Luo, et al. “Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance).” Clin Cancer Res, December 29, 2021. https://doi.org/10.1158/1078-0432.CCR-21-2386.

PMID
34965953
Full Text

Nixon, Andrew B., Alexander B. Sibley, Yingmiao Liu, Ace J. Hatch, Chen Jiang, Flora Mulkey, Mark D. Starr, et al. “Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance).” Clin Cancer Res, December 29, 2021. https://doi.org/10.1158/1078-0432.CCR-21-2389.

PMID
34965954
Full Text

Lipsyc-Sharf, Marla, Sui Zhang, Fang-Shu Ou, Chao Ma, Nadine Jackson McCleary, Donna Niedzwiecki, I-Wen Chang, et al. “Survival in Young-Onset Metastatic Colorectal Cancer: Findings from Cancer and Leukemia Group B (Alliance)/SWOG 80405.” Journal of the National Cancer Institute, October 12, 2021. https://doi.org/10.1093/jnci/djab200.

PMID
34636852
Full Text

Taniguchi, Hiroya, Takayuki Yoshino, Kensei Yamaguchi, Kentaro Yamazaki, Andrew B. Nixon, Josep Tabernero, Eric Van Cutsem, et al. “Clinical development and evaluation of a VEGF-D assay in plasma from patients with metastatic colorectal cancer in the RAISE study.” Current Medical Research and Opinion 37, no. 10 (October 2021): 1769–78. https://doi.org/10.1080/03007995.2021.1940908.

PMID
34229554
Full Text

Wetzel-Strong, Sarah E., Shantel Weinsheimer, Jeffrey Nelson, Ludmila Pawlikowska, Dewi Clark, Mark D. Starr, Yingmiao Liu, et al. “Pilot investigation of circulating angiogenic and inflammatory biomarkers associated with vascular malformations.” Orphanet Journal of Rare Diseases 16, no. 1 (September 3, 2021): 372. https://doi.org/10.1186/s13023-021-02009-7.

PMID
34479577
Full Text

Choueiri, Toni K., Yousef Zakharia, Sumanta Pal, Judit Kocsis, Russell Pachynski, Alexandr Poprach, Andrew B. Nixon, et al. “Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR).” The Oncologist 26, no. 7 (July 2021): 560-e1103. https://doi.org/10.1002/onco.13777.

PMID
33829609
Full Text

Armstrong, Andrew J., Andrew B. Nixon, Andrea Carmack, Qian Yang, Tim Eisen, Walter M. Stadler, Robert J. Jones, et al. “Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-Clear Cell Renal Cell Carcinoma.” Clin Cancer Res 27, no. 12 (June 15, 2021): 3317–28. https://doi.org/10.1158/1078-0432.CCR-20-4504.

PMID
33593885
Full Text

Strickler, John H., Christel N. Rushing, Hope E. Uronis, Michael A. Morse, Donna Niedzwiecki, Gerard C. Blobe, Ashley N. Moyer, et al. “Cabozantinib and Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer.” Oncologist 26, no. 6 (June 2021): 465-e917. https://doi.org/10.1002/onco.13678.

PMID
33469991
Full Text

Armstrong, Andrew J., Andrew B. Nixon, Andrea Carmack, Qian Yang, Tim Eisen, Walter M. Stadler, Robert J. Jones, et al. “Correction: Angiokines Associated with Outcomes after Sunitinib or Everolimus Treatment in Patients with Non-Clear Cell Renal Cell Carcinoma.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 27, no. 12 (June 2021): 3503. https://doi.org/10.1158/1078-0432.ccr-21-1636.

PMID
34117029
Full Text

Dorry, Michael, Kevin Davidson, Rajesh Dash, Rachel Jug, Jeffrey M. Clarke, Andrew B. Nixon, and Kamran Mahmood. “Pleural effusions associated with squamous cell lung carcinoma have a low diagnostic yield and a poor prognosis.” Transl Lung Cancer Res 10, no. 6 (June 2021): 2500–2508. https://doi.org/10.21037/tlcr-21-123.

PMID
34295657
Full Text

Pages